In preparation for the World Parkinson Congress taking place in Barcelona in July, the World Parkinson Coalition (WPC) is…
Articles by Marisa Wexler, MS
People with Parkinson’s disease facing anxiety, depression, apathy, and other mental health challenges when diagnosed are more likely to…
The Parkinson’s Progression Markers Initiative (PPMI), a landmark study from The Michael J. Fox Foundation for Parkinson’s Research (MJFF)…
To celebrate Parkinson’s Awareness Month, Bent Water Brewing Company is releasing a beer, called Common Hope, with the aim…
AT-04 and AT-07, experimental therapies Attralus is developing to treat Parkinson’s disease and other neurodegenerative disorders, are able…
Older age at the onset of disease, high blood pressure, poor cognitive and motor function, and mutations in the APOE…
One year of treatment with Anavex 2-73 (blarcamesine) safely led to a reduction in symptom severity for 20 people…
Blocking the activity of the synuclein nitrase enzyme reduced the levels of toxic clumps of the alpha-synuclein protein and lessened…
PharmaTher Holdings has received guidance from the U.S. Food and Drug Administration (FDA) on the late-stage clinical development of…
A science team at Merck (known as MSD outside North America) is the winner of an $8.5 million…